Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Regina Barragan-Carrillo, MD, discusses a pilot study evaluating the use of camu camu in combination with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.
CytoDyn intends to submit its final study protocol to the FDA, engage a clinical research organization, and complete preparatory work to initiate the phase 2 trial.
Michael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.
Malate dehydrogenase 2 is a pivotal enzyme in the tricarboxylic acid cycle. Recent studies have highlighted the significant involvement of MDH2 in the pathogenesis and progression of diverse types of tumors, yet its precise mechanistic underpinnings remain elusive. This study revealed a ...
During a Case-Based Roundtable® event, Robert J. Motzer, MD, evaluated the available data for cabozantinib plus nivolumab and lenvatinib plus pembrolizumab as combination therapies for non–clear cell renal cell carcinoma.
SABR appears to be a viable option for patients with renal cell carcinoma (RCC), and the side effects of kidney radiation appear tolerable.
Out of the 34 cancers studied for a new report, 17 saw an increase of diagnoses in a younger demographic than in older generations
A key opinion leader explores the evolution of the treatment landscape for patients with advanced non-clear cell renal cell carcinoma (nccRCC), highlighting recent treatment options and sharing insights on factors influencing the selection of appropriate therapies.
A recent study, published in Cell, has identified the circadian rhythm of TILs as a key determinant in the efficacy of immunotherapy treatments such as CAR T-cell therapy and immune checkpoint blockade.
Clear cell renal cell carcinoma (ccRCC) is characterized by a high incidence and mortality rate. Despite advancements in therapeutic interventions, the prognosis for renal cancer patients remains suboptimal. Of late, methylation modifications have emerged as promising molecular targets for ...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.